PT - JOURNAL ARTICLE AU - Elisabeth Kahre AU - Lukas Galow AU - Manja Unrath AU - Luise Haag AU - Judith Blankenburg AU - Alexander H. Dalpke AU - Christian Lück AU - Reinhard Berner AU - Jakob P. Armann TI - Kinetics and seroprevalence of SARS-CoV-2 antibodies – a comparison of 3 different assays AID - 10.1101/2021.03.10.21253273 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.10.21253273 4099 - http://medrxiv.org/content/early/2021/03/12/2021.03.10.21253273.short 4100 - http://medrxiv.org/content/early/2021/03/12/2021.03.10.21253273.full AB - Purpose Comparing seroprevalence and antibody kinetics in three different commercially available assays for SARS-CoV-2.Methods Serostatus of COVID-19 patients was analyzed 5 months and 10 months after their infection, using three different assays: Diasorin LIAISON®, Euroimmun®, Abbott Diagnostics® ARCHITECT.Results Seropositivity at baseline differed significantly depending on the assay (Diasorin 81%, Euroimmun 83%, Abbott 59%). At follow-up antibody levels detected in the Diasorin assay were stable, while there was a significant loss in seropositivity in the Euroimmun and Abbott assays.Conclusion There are significant differences in SARS-CoV-2 antibody kinetics based on the specific assay used.Trial registration number, date of registration DRKS00022549, 29.07.2020 “retrospectively registered”Competing Interest StatementConflicts of interest/Competing interests: Alexander Dalpke, Reinhard Berner and Jakob Armann report grants from Federal State of Saxony during the conduct of the study. Clinical TrialDRKS00022549Funding StatementFunding: This study was supported by a grant by the Federal State of Saxony.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The AmbCoviDD19 study was approved by the Ethics Committee of the Technische Universitaet (TU) Dresden (BO-EK-137042020)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe share data if reasonable requests are received. Requests should be directed to the corresponding author at jakob.armann@uniklinikum-dresden.de